NAUT - Earnings announcements

SEATTLE, April 28, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 Business Highlights Initiated our Iterative Mapping Early Access Program, enabling broader access to our validated Tau proteoform assay, with Baylor College of Medicine as our first customer in a National Institutes of Health-funded cancer study.Advanced processing and analysis of Tau proteoform samples from collaborators, supporting platform validation and future scientific publications.Appointed Amber Faust as Vice President of Global Sale

SEATTLE, April 09, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the first quarter 2026 before market open on Tuesday, April 28, 2026. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and its

SEATTLE, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter 2025 and Fiscal Year 2025 Business Highlights Continued progress was made in processing and analyzing Tau proteoform samples from collaborators to support platform validation and expanding scientific publications. Externally generated Tau data measured on the Nautilus Voyager™ platform was presented at the World HUPO conference, and collaborators are advancing results toward submission for publication.Further progress was made

SEATTLE, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year 2025 before market open on Thursday, February 26, 2026. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle,

SEATTLE, Oct. 28, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Business Highlights Continued progress was made in processing Tau proteoform samples from collaborators in support of our goals of product validation and growing our publications. We expect to share this data at the upcoming World HUPO conference.Further progress was made in the development of a new broadscale assay format, which is intended to support our forthcoming commercial launch in late 2026.We expect to launch our

SEATTLE, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter 2025 before market open on Tuesday, October 28, 2025. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and it

SEATTLE, July 31, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2025. "In Q2, we achieved major milestones that underscore the continued advancement of our platform," said Sujal Patel, CEO of Nautilus Biotechnology. "Not only did we continue our momentum across both targeted and broadscale proteomic development efforts, but we also publicly shared the first scientific manuscript to feature novel data generated using the Nautilus Platform. The manuscript represents nearly a decade of pioneering work by our team and

SEATTLE, July 15, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the second quarter 2025 before market open on Thursday, July 31, 2025. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters i

SEATTLE, April 29, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2025. "In Q1, we saw continued development progress based on the results of internal verification and validation work we've done on our Tau proteoform assay," said Sujal Patel, CEO of Nautilus Biotechnology. "The assay's reproducibility, accuracy, dynamic range, and sample compatibility align closely with our anticipated launch specifications and with the requirements we continue to hear from potential customers and partners. We are confident that 202

SEATTLE, April 16, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today announced it will report financial results for the first quarter 2025 before market open on Tuesday, April 29, 2025. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and it

SEATTLE, Feb. 27, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2024. Reported total operating expenses for the fourth quarter of 2024 were $20.0 million, roughly equal to the fourth quarter of 2023, and $0.9 million above last quarter reflecting an ongoing focus on expense management;Announced an expectation that the launch of Nautilus' proteome analysis platform - instruments and reagents - will occur in late 2026;Announced a reduction in headcount of approximately 16% in order to appropriat

SEATTLE, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2024 before market open on Thursday, February 27, 2025. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattl

SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2024. "I'm excited about the expanding opportunity I see for proteomics and am pleased with the progress we're making as a business," said Sujal Patel, CEO of Nautilus. "We consistently receive positive feedback from researchers around the world as they tell us of their desire to explore the proteome more deeply and more broadly, and of the significant limitations of what's currently available. It is becoming ever more apparent that they understand

SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the third quarter 2024 before market open on Tuesday, October 29, 2024. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and i

SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2024. "In Q2, we saw continued progress against core development goals for each of the components of our platform," said Sujal Patel, CEO of Nautilus. "We believe we are pioneering a fundamentally new approach that holds the potential to overcome the limitations of traditional and peptide-based protein analysis methods and to unlock the value of the proteome – both in targeted proteoform analysis and broadscale discovery – something we continue to vie

SEATTLE, July 09, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the second quarter 2024 before market open on Tuesday, July 30, 2024. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and its

SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024. "We continued to make solid progress against our core development goals in Q1," said Sujal Patel, CEO of Nautilus.   "We remain incredibly focused on increasing the scale, stability, and reproducibility of our consumables, assay, instrument, and software and continue to see meaningful gains along each of those dimensions. We are clear-eyed about what work remains to be done and confident that we have a foundational understanding of what is requ

SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and it

SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023. "2023 was a year of significant accomplishment and foundational progress for Nautilus; progress that will continue to build our momentum as we move through 2024 and into the planned launch of our proteome analysis platform", said Sujal Patel, CEO of Nautilus. "We are building a groundbreaking, ‘first-in-the-world' platform designed to unlock significant breakthroughs in biological research. Doing so requires that a number of

SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2023 before market open on Wednesday, February 28, 2024. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seat

SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2023. "I'm very pleased with the progress Nautilus made in Q3 as we continue our drive towards commercial readiness", said Sujal Patel, CEO of Nautilus.   "Continuing to increase the scale and robustness of the platform remains a key area of focus as we ready the platform for launch next year. With an increasing focus on proteomics by the scientific community, moves by major life science companies to expand their proteomics-related offerings,

SEATTLE, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter before market open on Tuesday, October 31, 2023. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and its re

SEATTLE, Wash., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2023. "I'm excited by the solid progress we made in Q2 against some of our foundational scientific and development goals and in the ways we continue to prepare ourselves for our commercial launch," said Sujal Patel, CEO of Nautilus. "The type of transformational innovation that Nautilus plans to bring to market next year requires that a significant number of platform elements weave together into a seamless whole: sample preparation, affinity re

SEATTLE, July 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the second quarter before market open on Wednesday, August 2, 2023. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle and its research and

SEATTLE, May 02, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2023. Recent Highlights Announced the three winners of Nautilus' First Access Challenge, representing a diverse set of investigators and spanning a wide range of areas of study across aging, inflammatory disorders, and cancer. The winners' samples will be run as part of Nautilus' Early Access Program.The company was granted 4 new US Patents in the first quarter of 2023, raising Nautilus' total to 12 granted US Patents.Total operating expenses for the

SEATTLE, April 18, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the first quarter before market open on Tuesday, May 2, 2023. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle and its research and d

SEATTLE, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2022. Recent Highlights Announced a strategic partnership with the Translational Genomics Research Institute (TGen) to explore the utility of the Nautilus platform for studying specific protein targets in diffuse intrinsic pontine glioma (DIPG), a rare and often fatal childhood cancer.Presented a poster at the HUPO World Congress that demonstrated decoding of a model protein from an experiment of several dozen multi-affini

SEATTLE, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2022 before market open on Thursday, February 23, 2023. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seatt

SEATTLE, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2022. Recent Highlights Reported total operating expenses for the third quarter of 2022 of $15.8 million, modestly higher compared to the same quarter last year reflecting increased investment in the development of our platform moderated by an ongoing focus on expense management.Continued progress against core scientific and engineering goals in the third quarter of 2022 while increasing experimental scale and continuing to advance the quality an

SEATTLE, Oct. 05, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the third quarter 2022 before market open on Tuesday, November 1, 2022. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters

SEATTLE, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule proteome analysis, today reported financial results for the second quarter ended June 30, 2022. Recent Highlights Reported total operating expenses for the second quarter of 2022 of $15.5 million, down sequentially from $16.0 million in the first quarter of 2022 and from $16.8 million in the fourth quarter of 2021.Announced the hiring of industry veterans Eric Spence and Ken Kuhn as VP of Instrument Engineering and VP of Reagent and Process Development, respectively, to strengthen Nautilus' development efforts.Provided guidance that anticipates th

SEATTLE, July 13, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the second quarter 2022 before market open on Tuesday, August 2nd, 2022. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc. Based in Seattle, Washington

SEATTLE, May 03, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule proteome analysis, today reported financial results for the first quarter ended March 31, 2022. Recent Highlights Shared a manuscript titled "Development of highly dense and scalable single protein arrays for single-molecule studies" that demonstrates an important element of creating high quality, high-density, single-molecule protein arrays that allow massively parallel detection and identification.Shared results from our research collaboration with Genentech at the annual meeting of the US Human Proteome Organization in a poster titled ‘Single-Mo

SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the first quarter 2022 before market open on Tuesday, May 3rd, 2022. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc. With its corporate headquarters

SEATTLE, Feb. 24, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2021. Fiscal Year 2021 Highlights In June, completed a business combination transaction with ARYA Sciences Acquisition Corp III and became a publicly traded company, with gross proceeds from this transaction totaling approximately $345.5 million.Announced research collaborations with top tier research partners at both Amgen, and The University of Texas MD Anderson Cancer Center.Announced a strategic partnership with Ab

SEATTLE, Jan. 27, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the fourth quarter and full year 2021 before market open on Thursday, February 24th, 2022. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc. Based in S

SEATTLE, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today reported financial results for the third quarter ended September 30, 2021. Recent Highlights Initiated a strategic partnership with Abcam, a world leader in the design and production of commercial antibodies, which we expect to accelerate our technology development pipeline and provide access to antibody development expertise that we believe will enhance protein detection in our platform.Signed our second and third research collaborations, one with a global pharmaceutical company and th

SEATTLE, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the third quarter of fiscal year 2021 before market open on Tuesday, November 2nd, 2021. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.

SEATTLE, Aug. 10, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome, today reported financial results for the second quarter ended June 30, 2021. Recent Highlights Completed business combination transaction with ARYA Sciences Acquisition Corp III (the "Business Combination") and became a publicly traded company on June 10, 2021, with gross proceeds from this transaction totaling approximately $345.5 million.Continued to meet key internal milestones across a range of platform design and science activities in support of a planned late-2